• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

MASLD screening and diagnostic algorithms are interchangeable with existing NAFLD literature.

作者信息

Arora Umang, Biswas Sagnik, Aggarwal Sandeep, Duseja Ajay

机构信息

Department of Gastroenterology and Human Nutrition, All India Institute of Medical Sciences, Delhi, India.

Department of Hepatology, Post Graduate Institute of Medical Education and Research, Chandigarh, India.

出版信息

J Hepatol. 2024 Feb;80(2):e89-e91. doi: 10.1016/j.jhep.2023.10.032. Epub 2023 Nov 3.

DOI:10.1016/j.jhep.2023.10.032
PMID:37925079
Abstract
摘要

相似文献

1
MASLD screening and diagnostic algorithms are interchangeable with existing NAFLD literature.代谢功能障碍相关脂肪性肝病（MASLD）的筛查和诊断算法与现有的非酒精性脂肪性肝病（NAFLD）文献是可互换的。
J Hepatol. 2024 Feb;80(2):e89-e91. doi: 10.1016/j.jhep.2023.10.032. Epub 2023 Nov 3.
2
[Analysis of non-alcoholic fatty liver disease differences from metabolic dysfunction-associated fatty liver disease based on clinical features].基于临床特征分析非酒精性脂肪性肝病与代谢功能障碍相关脂肪性肝病的差异
Zhonghua Gan Zang Bing Za Zhi. 2024 Apr 20;32(4):346-353. doi: 10.3760/cma.j.cn501113-20231022-00153.
3
Association between triglyceride-glucose related indices and mortality among individuals with non-alcoholic fatty liver disease or metabolic dysfunction-associated steatotic liver disease.甘油三酯-葡萄糖相关指标与非酒精性脂肪性肝病或代谢相关脂肪性肝病患者死亡的相关性。
Cardiovasc Diabetol. 2024 Jul 4;23(1):232. doi: 10.1186/s12933-024-02343-7.
4
Changing from NAFLD to MASLD: Similar cumulative incidence of reflux esophagitis between NAFLD and MASLD.从非酒精性脂肪性肝病转变为代谢功能障碍相关脂肪性肝病：非酒精性脂肪性肝病和代谢功能障碍相关脂肪性肝病之间反流性食管炎的累积发病率相似。
Clin Mol Hepatol. 2024 Jan;30(1):121-123. doi: 10.3350/cmh.2023.0437. Epub 2023 Dec 4.
5
Clinical profiles and mortality rates are similar for metabolic dysfunction-associated steatotic liver disease and non-alcoholic fatty liver disease.代谢相关脂肪性肝病和非酒精性脂肪性肝病的临床特征和病死率相似。
J Hepatol. 2024 May;80(5):694-701. doi: 10.1016/j.jhep.2024.01.014. Epub 2024 Jan 27.
6
[Diagnosis and evaluation of metabolic dysfunction associated steatotic liver disease (MASLD)].代谢功能障碍相关脂肪性肝病（MASLD）的诊断与评估
Rev Med Interne. 2024 Jan;45(1):41-47. doi: 10.1016/j.revmed.2023.10.438. Epub 2023 Dec 29.
7
From NAFLD to MASLD: When metabolic comorbidity matters.从非酒精性脂肪性肝病到代谢相关性脂肪性肝病：当代谢合并症起重要作用时。
Ann Hepatol. 2024 Mar-Apr;29(2):101281. doi: 10.1016/j.aohep.2023.101281. Epub 2023 Dec 21.
8
Prognosis of biopsy-confirmed metabolic dysfunction- associated steatotic liver disease: A sub-analysis of the CLIONE study.经活检证实的代谢相关脂肪性肝病的预后：CLIONE 研究的亚分析。
Clin Mol Hepatol. 2024 Apr;30(2):225-234. doi: 10.3350/cmh.2023.0515. Epub 2024 Jan 24.
9
Changing from NAFLD to MASLD: Similar prognosis of patients with HCC under atezolizumab/bevacizumab treatment between NAFLD and MASLD.从非酒精性脂肪性肝病转变为代谢相关脂肪性肝病：在阿替利珠单抗/贝伐单抗治疗下，非酒精性脂肪性肝病和代谢相关脂肪性肝病患者发生肝细胞癌的预后相似。
Clin Mol Hepatol. 2024 Apr;30(2):263-265. doi: 10.3350/cmh.2023.0557. Epub 2024 Jan 18.
10
Prognostic value of metabolic dysfunction-associated steatotic liver disease over coronary computed tomography angiography findings: comparison with no-alcoholic fatty liver disease.代谢相关脂肪性肝病与冠状动脉 CT 血管造影结果的预后价值比较：与非酒精性脂肪肝的比较。
Cardiovasc Diabetol. 2024 May 10;23(1):167. doi: 10.1186/s12933-024-02268-1.

引用本文的文献

1
Adoption of the New Nomenclature of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) by the Indian National Association for Study of the Liver (INASL): Implications for the INASL Guidance Paper on NAFLD.印度国家肝脏研究协会（INASL）采用代谢功能障碍相关脂肪性肝病（MASLD）新命名法：对INASL非酒精性脂肪性肝病指南文件的影响
J Clin Exp Hepatol. 2025 Sep-Oct;15(5):102590. doi: 10.1016/j.jceh.2025.102590. Epub 2025 May 16.
2
Expression Analysis of Circulating miR-21, miR-34a and miR-122 and Redox Status Markers in Metabolic Dysfunction-Associated Steatotic Liver Disease Patients with and Without Type 2 Diabetes.伴有和不伴有2型糖尿病的代谢功能障碍相关脂肪性肝病患者循环miR-21、miR-34a和miR-122及氧化还原状态标志物的表达分析
Int J Mol Sci. 2025 Mar 7;26(6):2392. doi: 10.3390/ijms26062392.
3
Association between neutrophil-albumin ratio and ultrasound-defined metabolic dysfunction-associated fatty liver disease in U.S. adults: evidence from NHANES 2017-2018.美国成年人中性粒细胞与白蛋白比值和超声定义的代谢功能障碍相关脂肪性肝病之间的关联：来自2017 - 2018年美国国家健康与营养检查调查（NHANES）的证据
BMC Gastroenterol. 2025 Jan 17;25(1):20. doi: 10.1186/s12876-025-03612-9.
4
Metabolic Dysfunction-associated Steatotic Liver Disease and Type 2 Diabetes: A Deadly Synergy.代谢功能障碍相关脂肪性肝病与2型糖尿病：致命协同作用
touchREV Endocrinol. 2024 Oct;20(2):5-9. doi: 10.17925/EE.2024.20.2.2. Epub 2024 Apr 23.
5
Genetically predicted metabolites mediate the association between immune cells and metabolic dysfunction-associated steatotic liver disease: a mendelian randomization study.遗传预测代谢物介导免疫细胞与代谢功能障碍相关脂肪性肝病的关联：一项孟德尔随机研究。
Lipids Health Dis. 2024 Aug 16;23(1):249. doi: 10.1186/s12944-024-02245-3.
6
Liver diseases and hepatocellular carcinoma in the Asia-Pacific region: burden, trends, challenges and future directions.亚太地区的肝脏疾病和肝细胞癌：负担、趋势、挑战和未来方向。
Nat Rev Gastroenterol Hepatol. 2024 Dec;21(12):834-851. doi: 10.1038/s41575-024-00967-4. Epub 2024 Aug 15.
7
Neutrophil to albumin ratio: a biomarker in non-alcoholic fatty liver disease and with liver fibrosis.中性粒细胞与白蛋白比值：非酒精性脂肪性肝病及肝纤维化中的一种生物标志物。
Front Nutr. 2024 Apr 8;11:1368459. doi: 10.3389/fnut.2024.1368459. eCollection 2024.
8
Phosphorylation: new star of pathogenesis and treatment in steatotic liver disease.磷酸化：脂肪性肝病发病机制和治疗的新靶点。
Lipids Health Dis. 2024 Feb 17;23(1):50. doi: 10.1186/s12944-024-02037-9.